Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.
Saved in:
| Title: | Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis. |
|---|---|
| Authors: | Zhou J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China., Xing L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Miao Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Qin S; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Zhang R; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Tang H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Xia Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com., Zhu H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com., Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Jun; Vol. 43 (3), pp. 451-459. Date of Electronic Publication: 2025 May 31. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
